Rationale: Plasma apolipoprotein (apo)M is mainly associated with high-density lipoprotein (HDL). HDL-bound apoM is antiatherogenic in vitro. However, plasma apoM is not associated with coronary heart disease in humans, perhaps because of a positive correlation with plasma low-density lipoprotein (LDL). Objective: We explored putative links between apoM and very-low-density (VLDL)/LDL metabolism and the antiatherogenic potential of apoM in vivo. Methods and Results: Plasma apoM was increased Ϸ2.1 and Ϸ1.5 fold in mice lacking LDL receptors (Ldlr ؊/؊ ) and expressing dysfunctional LDL receptor-related protein 1 (Lrp1 n2/n2 ), respectively, but was unaffected in apoE-deficient (ApoE ؊/؊ ) mice. Thus, pathways controlling catabolism of VLDL and LDL affect plasma apoM. Overexpression (Ϸ10-fold) of human apoM increased (50% to 70%) and apoM deficiency decreased (Ϸ25%) plasma VLDL/LDL cholesterol in Ldlr ؊/؊ mice, whereas apoM did not affect plasma VLDL/LDL in mice with intact LDL receptors. Moreover, plasma clearance of apoM-enriched VLDL/LDL was slower than that of control VLDL/LDL in mice lacking functional LDL receptors and LRP1, suggesting that apoM impairs the catabolism of VLDL/LDL that occurs independently of the LDL receptor and LRP1. ApoM overexpression decreased atherosclerosis in ApoE ؊/؊ (60%) and cholate/cholesterol-fed wild-type mice (70%). However, in Ldlr ؊/؊ mice the antiatherogenic effect of apoM was attenuated by its VLDL/LDL-raising effect. Conclusion: The data suggest that defect LDL receptor function leads to increased plasma apoM concentrations, which in turn, impairs the removal of VLDL/LDL from plasma. This mechanism opposes the otherwise antiatherogenic effect of apoM. (Circ Res. 2010;106:1624-1634.)
P lasma lipoproteins play a major role as risk factors for cardiovascular disease. ApoB-containing very-lowdensity lipoprotein (VLDL) and low-density lipoprotein (LDL) are proatherogenic whereas the apolipoprotein (apo)A-I-containing high-density lipoprotein (HDL) have antiatherogenic properties. [1] [2] [3] HDL comprises a heterogeneous class of lipoproteins which in addition to apoA-I contains Ͼ40 different proteins one of which is apolipoprotein M (apoM). 4 ApoM is produced in liver and kidney. 5, 6 Liver apoM is secreted to plasma, whereas kidney apoM is secreted into the urine. 7 The plasma concentration of apoM is Ϸ1 mol/L, ie, comparable to that of apoB (Ϸ2 mol/L) but lower than that of apoA-I (Ϸ40 mol/L). 8 The major fraction of plasma apoM resides in HDL. 9, 10 A smaller fraction is present in apoB-containing lipoproteins such as LDL and triglyceride-rich VLDL. 9, 10 Immuno-depletion studies sug-gest that Ϸ5% of plasma HDL and 1 to 2% of plasma LDL particles contain apoM. 10 The structure of apoM lacks the amphipathic motifs which normally attach apolipoproteins to the lipid surface of plasma lipoproteins. 11 Instead, apoM is bound to plasma lipoproteins via its preserved hydrophobic signal peptide which serves as an anchor for apoM in the lipid moiety of plasma lipoproteins. 12, 13 Results from 2 independent studies suggest that modest overexpression of human and mouse apoM retards development of atherosclerosis in transgenic mice. 14, 15 The antiatherogenic effect of apoM overexpression has been ascribed to a stimulatory effect of apoM on pre␤-HDL formation. 14 -16 Pre␤-HDL serves as an acceptor of ABCA1-mediated cholesterol efflux from foam cells, and as such promotes reverse cholesterol transport. 17 Accordingly, human apoM-containing HDL mediates more cholesterol efflux from macrophage-de-rived foam cells than apoM-free HDL. 10 Moreover, apoMcontaining HDL is a more efficient inhibitor of Cu 2ϩ -induced oxidation of LDL than apoM-free HDL. 10 Even though experimental studies thus imply antiatherogenic potentials of apoM, the plasma apoM concentration did not differ between individuals with cardiovascular disease and control subjects. 18 The reason for this apparent discrepancy is unknown but may relate to a rather strong positive association (rϷ0.28 to 0.42) between the plasma apoM and LDL-cholesterol concentrations. 8, 16, 18 Thus, the potential beneficial effect of a high plasma apoM is confounded by the coexistence of elevated LDL which has been consistent in several human studies. 8, 16, 18 The association between plasma LDL cholesterol and apoM could reflect that the plasma apoM concentration is determined by the metabolism of LDL, that apoM affects the plasma LDL concentration, or a combination. It is, however, unknown how the putative link between apoM and apoB metabolism might affect the overall atherogenicity of plasma apoM.
On secretion of apoB48-containing chylomicrons from the intestine or apoB100-containing VLDL from the liver, the triglyceride-rich lipoproteins, which also contain apoE are subjected to the action of lipoprotein lipase. The apoB48containing chylomicrons are converted into remnant particles that are rapidly catabolized, primarily in the liver. Liverderived apoB100-containing VLDL gives rise to IDL and ultimately LDL particles. 19 Normal subjects loose 40 to 50% of their apoB/apoE-containing VLDL/IDL particles from plasma before conversion into LDL. 20 The hepatic clearance of LDL involves binding of apoB100 to the LDL receptor. 21 ApoE also binds to the LDL receptor. 22 Lack of functional LDL receptors causes familial hypercholesterolemia (FH). 2 FH thus results in decreased clearance of plasma LDL, but also increased production rates of apoB-containing lipoproteins. 23, 24 Moreover, FH patients apparently loose few of their apoB/apoE-containing VLDL/IDL particles before conversion into LDL. Despite the decreased fractional catabolic rate of LDL, studies in WHHL-rabbits showed that the LDLdeficient liver still removes large numbers of LDL particles. 25 In the absence of LDL receptors, lipoprotein uptake in the liver appears at least partly dependent on apoE, as judged from studies in mice. 26 Thus, VLDL and IDL can be removed in the liver via apoE-binding to heparan sulfate and LRP1 (LDL receptor-related protein 1). 27, 28 Nevertheless, LRP1deficient mice as opposed to LDL receptor-deficient mice display no or only minor increases in plasma VLDL/LDL 29 implying that LRP1 is not a major receptor for lipoprotein clearance in the setting of preserved LDL receptor function. Lack of LRP1 in LDL receptor-deficient mice, however, causes some increase in plasma VLDL/LDL suggesting that LRP1 can function as partial backup for the LDL receptor.
Little is known about the mechanisms and relative contributions of other non-LDL receptor pathways for lipoprotein uptake in the liver. Studies in genetically modified mice indicate that other receptors such as LRP5 30 and SRBI, 31 as well as proteoglycans may play a role.
In the present study, we have examined links between VLDL/LDL and apoM metabolism by measuring plasma apoM in mice with elevated VLDL/LDL levels attributable to hepatic overproduction (in human apoB transgenic mice [ApoB-Tg]), decreased LDL receptor-mediated clearance (in LDL receptor-deficient mice [Ldlr Ϫ/Ϫ ]), or decreased non-LDL receptor-mediated clearance (in apoE-deficient mice [ApoE Ϫ/Ϫ ]) and mice with defect LRP1 (Lrp1 n2/n2 ). Moreover, we have assessed the impact of apoM on the metabolism of VLDL/LDL and atherosclerosis using two lines of human apoM transgenic mice (ApoM-Tg N and ApoM-Tg H ) and apoM deficient mice (ApoM Ϫ/Ϫ ). The results suggest that defects in the LDL receptor or LRP1 result in increased plasma apoM and that the increased plasma apoM in turn results in delayed clearance of VLDL/LDL particles via non-LDL receptor-mediated pathways. The results also suggest that increased plasma apoM protects against atherosclerosis, but that the beneficial effect of apoM is opposed by the VLDL/LDL-raising effect in the setting of LDL receptor deficiency.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Impact of Perturbed LDL Metabolism on Mouse ApoM
Mouse apoM was measured with ELISA in wild-type (Wt), Ldlr Ϫ/Ϫ , ApoE Ϫ/Ϫ , Lrp1 n2/n2 , Lrp1 n2/n2 Ldlr Ϫ/Ϫ , Lrp1 n2/n2 ApoE Ϫ/Ϫ , and ApoB-Tg mice. ApoB expression in human apoB transgenic mice was inhibited in vivo with an apoB antisense oligonucleotide. The dϽ1.063 and dϾ1.063 g/mL plasma lipoproteins were separated with fixed density ultracentrifugation. Plasma lipids were determined with enzymatic assays.
In Vivo Metabolism of ApoM and ApoM-Containing VLDL/LDL
The exchange of apoM between lipoproteins was examined in vivo by injecting human apoM-containing VLDL/LDL or HDL into Ldlr Ϫ/Ϫ mice and Wt mice. Human apoM in individual lipoprotein fractions was determined by gel filtration of recipient mouse plasma and human apoM ELISA and Western blotting of isolated fractions. The turnover of apoM-enriched VLDL/LDL versus apoM-poor VLDL/LDL was determined by iodination of isolated VLDL/LDL from ApoM-Tg H Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice with 125 I and 131 I. The labeled lipoproteins were coinjected into Ldlr Ϫ/Ϫ and Lrp1 n2/n2 Ldlr Ϫ/Ϫ mice and the plasma decay followed by ␥-counting of plasma (10 L) from the recipient mice. ApoM-Tg N mice were fed a cholic-acid/cholesterol-enriched diet to induce hyperlipidemia. Plasma lipoproteins were separated with gel filtration chromatography; pooled fractions were used for Western blotting with antibodies against mouse apolipoproteins. Aortic atherosclerosis was quantified as en face lesion areas and/or oil-red O staining lesions in histological cross sections of the aortic root.
Impact of ApoM on Lipoproteins and Atherosclerosis

Results
Deficiency of the LDL Receptor or LRP1 Increases Plasma ApoM
To assess the impact of perturbed VLDL/LDL metabolism on plasma apoM concentrations, we quantified apoM with ELISA (Online Figure I) in Wt mice and in mice with impaired clearance of apoB-and apoE-containing lipoproteins.
Compared with Wt mice, plasma apoM was increased Ϸ110% (PϽ0.0005) in Ldlr Ϫ/Ϫ mice with elevated VLDL/ LDL ( Figure 1A and 1B). Mice with a knock-in mutation in the NPxYxxL motif of LRP1 designed to attenuate LRP1mediated lipoprotein internalization (Lrp1 n2/n2 ) also had increased plasma apoM Ϸ50% (PϽ0.005) despite less pronounced elevation of the plasma cholesterol concentration ( Figure 1A and 1B). 32 Combined deficiency of the LDL receptor and LRP1 caused a further increase of plasma apoM ( Figure 1B) . In contrast, total plasma apoM was not significantly increased in ApoE Ϫ/Ϫ mice irrespective of the pronounced elevation of VLDL/LDL cholesterol ( Figure 1A and 1B). Moreover, apoE-deficiency completely abolished the increase of plasma apoM in Lrp1 n2/n2 mice ( Figure 1B) .
In a subset of the mice, we used ultracentrifugation of plasma to assess to what extent the increase in total plasma apoM in Ldlr Ϫ/Ϫ and Lrp1 n2/n2 mice reflected increased apoM in the VLDL/LDL (dϽ1.063 g/mL) or in the HDL (dϾ1.063 g/mL) fraction. Compared to Wt mice, apoM in the VLDL/LDL fraction was significantly increased in Ldlr Ϫ/Ϫ and Lrp1 n2/n2 mice (Online Figure II, A) . Nevertheless, the major portion of plasma apoM was recovered in HDL (Online Figure II , A) and the increase of total plasma apoM in Ldlr Ϫ/Ϫ and Lrp1 n2/n2 mice therefore mainly reflected increases of HDL-associated apoM (Online Figure II, A) . Combined, the results, which were reiterated by Western blotting against apoM (data not shown), suggest that deficiency of LDL receptors or impairment of LRP1 increases HDL-associated apoM in an apoE-dependent manner. Additional Western blotting examinations suggested that HDLassociated apoE like HDL-associated apoM is increased in Ldlr Ϫ/Ϫ mice (Online Figure II, B ). This result further supports the notion that LDL receptor deficiency affects the concentration of a subset of HDL particles containing apoM and/or apoE.
Overexpression of ApoB Decreases Plasma ApoM
LDL receptor deficiency results in impaired clearance of apoB-containing lipoproteins but also in increased production rates. 23, 24 We assessed the impact of elevated plasma LDLcholesterol exclusively caused by increased hepatic production on the concentration of plasma apoM. Heterozygous human ApoB-Tg mice with increased hepatic apoB-secretion displayed increased LDL-cholesterol (Online Figure III , A and B) but decreased plasma apoM concentrations that were Ϸ50% of the level in littermate Wt mice ( Figure 1C ). We suspect that the reduction of plasma apoM by apoB overexpression may reflect (1) that apoM bound to LDL has a shorter half-life than apoM bound to plasma HDL because of the effective LDL receptor-mediated clearance of plasma LDL 33 ; and (2) that a larger fraction of plasma apoM will attach to LDL in ApoB-Tg mice with markedly elevated plasma LDL than in Wt mice with almost absent plasma LDL. Accordingly, lowering of the plasma LDL-cholesterol with an apoB-antisense oligonucleotide that targets both mouse and human apoB mRNA (Online Figure III , A and B) reversed plasma apoM concentrations to normal in ApoB-Tg mice ( Figure 1C ).
Exchange of ApoM Between Plasma Lipoproteins In Vivo
The predominant increase of HDL-associated apoM in mice with defect LDL receptor and/or LRP1 function as well as the lowering of apoM in ApoB-Tg mice could reflect either direct effects of a perturbed metabolism of apoBcontaining lipoproteins on apoM-containing HDL particles or exchange of apoM between HDL and VLDL/LDL particles (or a combination).
We examined whether apoM can exchange from HDL to VLDL/LDL particles in mice by injecting human apoMenriched HDL (from ApoM-Tg H mice) into Ldlr Ϫ/Ϫ mice with high VLDL/LDL cholesterol or Wt mice. Already 5 minutes after the injection a significant fraction of the initially HDL-associated apoM was recovered in the VLDL/LDL fraction of recipient Ldlr Ϫ/Ϫ mice (Figure 2A and 2B) but remained in the HDL fraction of recipient Wt mice (Online Figure IV, A) . We also examined the distribution of VLDL/ LDL-associated apoM to HDL particles by injecting human apoM-enriched VLDL/LDL into recipient Wt or Ldlr Ϫ/Ϫ mice. In Wt recipient mice, the vast portion of the VLDL/ LDL-derived human apoM was recovered in HDL after 5 minutes (Figure 2A and 2C) . A less pronounced exchange of human apoM to HDL was seen in Ldlr Ϫ/Ϫ recipient mice (Online Figure IV, B ). The redistribution of apoM among the lipoproteins of the recipient mice was consistent also when analyzing plasma from the recipient mice at 180 minutes after the injections (data not shown). These results show that apoM can rapidly exchange between plasma lipoproteins.
ApoM Increases Plasma VLDL-and LDL-Cholesterol in Ldlr ؊/؊ Mice
In Wt mice, overexpression of apoM doubles the plasma concentration of apoE in HDL and increases HDL cholesterol by Ϸ20%. 14 We have, however, not seen any in-or decrease of plasma VLDL/LDL-cholesterol in Wt mice that overexpress human apoM or lack endogenous apoM. 14 Nevertheless, it became apparent that apoM affects the metabolism of apoB-and apoE-containing lipoproteins when we crossed Ldlr Ϫ/Ϫ and ApoE Ϫ/Ϫ mice with a line of human apoM transgenic mice that overexpress apoM Ϸ10-fold (ApoM-Tg H ).
The plasma cholesterol and triglyceride concentrations were increased in ApoM-Tg H Ldlr Ϫ/Ϫ mice compared to littermate Ldlr Ϫ/Ϫ control mice and the difference in plasma cholesterol was further accentuated to Ϸ70% (37.4Ϯ4.4 versus 21.9Ϯ2.3 mmol/L, PϽ0.01) when the mice were fed a Western-type diet (Table) . Gel filtration chromatography showed that the increase in plasma cholesterol reflected increases of both VLDL-and LDL-cholesterol whereas HDLcholesterol appeared unaffected ( Figure 3A) . Western blot analysis of lipoprotein fractions from the gel filtration column showed that apoM overexpression increased the content of apoB48, apoB100, and apoE in the VLDL and LDL fractions ( Figure 3B) . Notably, the effect of apoM overexpression on apoB48 (which cannot bind the LDL receptor) was more pronounced than the effect on apoB100 (mainly cleared via the LDL receptor). 21,29,34 -36 ApoM overexpression also increased apoE in HDL ( Figure 3B) .
In contrast to the effect of apoM overexpression in Ldlr Ϫ/Ϫ mice, the total plasma cholesterol and triglyceride concentrations were similar in ApoM-Tg H ApoE Ϫ/Ϫ (13.6Ϯ0.6 and 1.5Ϯ0.2 mmol/L, respectively, nϭ7) and ApoE Ϫ/Ϫ littermate controls (13.7Ϯ0.8 and 1.1Ϯ0.1 mmol/L, respectively, nϭ9) (Table) . Accordingly, there was no discernable difference between ApoM-Tg H ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ mice when analyzing gel filtration profiles of plasma lipoproteins ( Figure  3C ) and VLDL/LDL-associated apoB48 and apoB100 by Western blotting (Figure 3D ).
To further examine the effect of apoM on plasma VLDL/ LDL in Ldlr Ϫ/Ϫ mice, we bred ApoM Ϫ/Ϫ mice with Ldlr Ϫ/Ϫ mice. ApoM deficiency had the opposite effect of apoM overexpression on plasma lipids. It decreased plasma triglycerides by Ϸ35% (PϽ0.05) in chow-fed Ldlr Ϫ/Ϫ mice and total plasma cholesterol concentration by Ϸ25% when the mice were fed a Western-type diet (PϽ0.01) (Table) . The VLDL and LDL cholesterol concentrations were lower in ApoM Ϫ/Ϫ Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ controls as judged from gel filtration chromatography analyses ( Figure  3E ). Opposite to the effect of apoM overexpression in Ldlr Ϫ/Ϫ mice, deficiency of apoM decreased the level of apoB48 in VLDL and LDL ( Figure 3F ). ApoM deficiency also decreased apoE, both in LDL and HDL ( Figure 3F ). ApoM Ϫ/ϩ Ldlr Ϫ/Ϫ mice displayed no significant change in the total plasma cholesterol concentration or plasma gel filtration profile as compared with Ldlr Ϫ/Ϫ mice (data not shown). Figure 3B ) were labeled with, respectively, 125 I and 131 I (or vice versa) and coinjected into recipient Western-type diet fed Ldlr Ϫ/Ϫ mice. The plasma clearance of *I-VLDL/LDL from ApoM-Tg H Ldlr Ϫ/Ϫ mice was slower than that of *I-VLDL/LDL from Ldlr Ϫ/Ϫ control mice (data not shown). To further test whether delayed clearance might be dependent on LRP1, we repeated the experiment ( Figure  4A ) and in addition compared the clearance of human apoM-enriched VLDL/LDL with that of apoM-poor VLDL/ LDL in mice lacking both the LDL receptor and functional LRP1. The clearance of the apoM-enriched VLDL/LDL was lower than that of apoM poor VLDL/LDL both in Ldlr Ϫ/Ϫ and in Lrp1 n2/n2 Ldlr Ϫ/Ϫ mice ( Figure 4B ).
Impaired Clearance of ApoM-Enriched VLDL/LDL in Ldlr
ApoM readily exchanges between plasma lipoprotein (vide supra). Hence, a larger fraction of the radioactivity from apoM-enriched VLDL/LDL than from apoM-poor VLDL/ Nonfasting plasma lipids (meansϮSEM) were measured at 4 -5 weeks of age when all mice were on a chow diet and at 20 weeks of age after feeding a Western-type diet for 16 weeks unless otherwise indicated. *PՅ0.05 and †Pϭ0.08 compared to the appropriate littermate control mice. ‡Mice with a C57B6/J background were a fed cholate/cholesterol-containing diet for 16 weeks. §ApoE Ϫ/Ϫ mice were fed a chow diet for 16 weeks (similar results were obtained in 5-week-old mice). ND indicates not determined.
LDL was recovered in HDL-sized lipoproteins of the recipient mice (Online Figure V, A) . Importantly, however, like total plasma radioactivity (Figure 4 ), the VLDL/LDLassociated radioactivity from apoM-poor VLDL/LDL was removed faster than that from apoM-enriched VLDL/LDL. Thus, after 6 hours 37% and 34% of the initial VLDL/LDL associated radioactivity from human apoM-enriched VLDL/LDL and 25% and 26% of the initial VLDL/LDL-associated radioactivity from apoM-poor VLDL/LDL particles remained in the plasma VLDL/LDL fraction of the Ldlr Ϫ/Ϫ and Lrp1 n2/n2 Ldlr Ϫ/Ϫ recipient mice, respectively (Online Figure V, B , shows the data from Ldlr Ϫ/Ϫ mice). Thus, the results are compatible with the notion that delayed clearance of VLDL/ LDL by an LDL receptor-and LRP1-independent pathway contributes to the increased plasma VLDL/LDL cholesterol in ApoM-Tg H Ldlr Ϫ/Ϫ mice.
Effect of ApoM on Atherosclerosis in Ldlr ؊/؊ Mice
We previously observed that a mild (Ϸ2-fold) overexpression of human apoM (ie, in ApoM-Tg N mice) results in Ϸ39% smaller atherosclerotic lesion areas in Ldlr Ϫ/Ϫ female mice. 14 In that study, the female ApoM-Tg N Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ controls had essentially identical plasma lipoprotein profiles, 14 suggesting that Ϸ2-fold overexpression of apoM has minor effects on VLDL/LDL catabolism in Ldlr Ϫ/Ϫ female mice. We have subsequently examined plasma lipoproteins and atherosclerosis in male ApoM-Tg N Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ controls. In accordance with the findings in ApoM-Tg H Ldlr Ϫ/Ϫ mice (Table) , male ApoM-Tg N Ldlr Ϫ/Ϫ mice had Ϸ28% increased total plasma cholesterol levels compared with Ldlr Ϫ/Ϫ littermate controls on a Western-type diet (Table) . Despite the higher plasma cholesterol concentration in ApoM-Tg N Ldlr Ϫ/Ϫ mice, there was no difference in atherosclerotic plaque areas between male ApoM-Tg N Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ littermate controls ( Figure 5A ).
We next examined the impact of extensive (Ϸ10-fold) apoM overexpression on atherosclerosis in ApoM-Tg H Ldlr Ϫ/Ϫ mice. The atherosclerotic plaque areas did not differ between male ApoM-Tg H Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ controls ( Figure 5B ) despite the Ϸ70% higher plasma cholesterol concentration in the ApoM-Tg H Ldlr Ϫ/Ϫ (Table) . These data are compatible with the results in ApoM-Tg N Ldlr Ϫ/Ϫ mice suggesting that overexpression of human apoM opposes the To examine the impact of endogenous apoM on atherosclerosis in Ldlr Ϫ/Ϫ mice, we compared ApoM Ϫ/Ϫ Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice. Deficiency of apoM, which decreased plasma VLDL-and LDL-cholesterol (Table) , reduced atherosclerotic plaque formation in female Ldlr Ϫ/Ϫ mice ( Figure  5D ). The mean atherosclerotic plaque area of mice that were heterozygous for the apoM targeted gene locus (ApoM Ϫ/ϩ Ldlr Ϫ/Ϫ ) were larger than that in ApoM Ϫ/Ϫ Ldlr Ϫ/Ϫ mice but did not differ significantly from that in the Ldlr Ϫ/Ϫ control mice ( Figure 5D ).
Effect of ApoM Overexpression on Atherosclerosis in Mouse Models With Intact LDL Receptors
The results obtained in Ldlr Ϫ/Ϫ mice with altered apoM expression suggested that the antiatherogenic effect of raising apoM was opposed by apoM increasing plasma VLDL/LDLcholesterol in the setting of LDL receptor deficiency. We therefore predicted that overexpression of apoM would substantially decrease atherosclerosis in hypercholesterolemic mice with intact LDL receptors. Support of this idea was obtained from two additional studies. First, we fed a proatherogenic cholate/cholesterol-enriched diet to ApoM-Tg N and Wt littermate female mice. ApoM overexpression did not significantly affect the extent of hypercholesterolemia in the cholate/cholesterol-fed mice. The plasma cholesterol and triglyceride concentrations were 7.0Ϯ0.3 and 0.1Ϯ0.0 mmol/L, respectively in ApoM-Tg N (nϭ14) mice and 6.1Ϯ0.4 and 0.1Ϯ0.0 mmol/L, respectively, in Wt mice (nϭ9) ( Table) and the gel filtration profiles of plasma lipoproteins were similar in the two groups (Online Figure  VI) . Because these mice have intact apoE expression, the latter finding argues against the possibility that the effect of apoM on plasma VLDL/LDL in Ldlr Ϫ/Ϫ mice depends on apoE. Remarkably, there was Ϸ70% less atherosclerosis in ApoM-Tg N compared with Wt control mice (Figure 6, left) . Second, we examined atherosclerotic lesions in 16-weeks-old ApoM-Tg H ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ littermate control mice with similar plasma lipoprotein levels ( Figure 3C ). The ApoM-Tg H ApoE Ϫ/Ϫ mice developed Ϸ60% less atherosclerosis than the ApoE Ϫ/Ϫ controls (Figure 6, right) .
Discussion
Previous studies have highlighted putative roles of apoM in HDL metabolism. 14, 15 ApoM has potential antiatherogenic functions, ie, stimulation of pre␤-HDL formation and potential contribution to the antioxidative effect of HDL. 14 In the present study, we used genetically modified mice to demonstrate hitherto unknown links between the metabolism of apoM and VLDL/LDL which affect the antiatherogenic potential of plasma apoM. The major findings were that (1) plasma apoM concentrations are increased when VLDL/LDL catabolism is decreased because of the absence of LDL receptors or fully functional LRP1; (2) the increase of plasma apoM is dependent on apoE and mainly occurs in HDL; (3) apoM readily exchanges between plasma lipoproteins in vivo; (4) overexpression or deficiency of apoM increases or decreases, respectively, the plasma levels of apoE and apoB48containing VLDL/LDL in Ldlr Ϫ/Ϫ mice even though the effect of modest apoM overexpression may be more pronounced in female than in male mice, whereas apoM overexpression has no effect on VLDL/LDL levels in mice with hypercholesterolemia attributable to absence of apoE or attributable to feeding a cholate/cholesterol-enriched diet; (5) the clearance of apoM-enriched VLDL/LDL likely is decreased in mice lacking both LDL receptors and functional LRP1; (6) apoM retards atherogenesis in ApoE Ϫ/Ϫ and cholate/cholesterol-fed mice, whereas the antiatherogenic effect is attenuated in Ldlr Ϫ/Ϫ mice; and (7) the antiathero-genic effect of apoM was more pronounced in male than in female mice in the setting of LDL receptor deficiency.
The crossroads between the metabolic pathways of plasma HDL and VLDL/LDL are incompletely understood. HDLassociated apoM was increased in Ldlr Ϫ/Ϫ and Lrp1 n2/n2 mice indicating that the activity of the receptors, known to control the catabolism of VLDL and LDL, also affects the catabolism of apoM-containing HDL particles. The impact of the LDL receptor and LRP1 on plasma apoM was a surprise because apoA-I and HDL-cholesterol are largely unaffected by LDL receptor deficiency. In fact, HDL-cholesterol and apoA-I are often slightly decreased in patients with homozygous FH. 37 Because the effect of defect LRP1 on plasma apoM was abolished in the absence of apoE, the results might reflect that a subset of HDL particles that contain apoM also contain apoE and are catabolized via the LRP1 and LDL receptors pathways. In accordance with this possibility, HDLassociated apoE was clearly increased in LDL receptordeficient mice. In addition, the data show that apoM readily exchanges between HDL and VLDL/LDL particles. Thus, the data also to some extent could reflect that a significant portion of apoM clearance occurs when apoM is bound to VLDL/LDL particles and that more apoM molecules "spillover" into the HDL fraction when VLDL/LDL clearance is impaired in LDL receptor-deficient mice.
The results thus provide new insight into human physiology by offering an explanation for the strong positive association between plasma LDL-cholesterol and apoM concentrations in humans. 8, 16, 18 In humans, the fractional catabolic rate of LDL is an important determinant of the normal interindividual variation in plasma LDL-cholesterol concentrations. 38 The present investigations in mice demonstrate that the plasma apoM concentration also is markedly affected by the LDL receptor pathway. Thus, it is likely that a decreased plasma clearance of VLDL/LDL will increase both plasma apoM and LDL-cholesterol and vice versa in humans.
We discovered a marked effect of apoM on VLDL/LDL metabolism when ApoM-Tg H and ApoM Ϫ/Ϫ mice were crossed with Ldlr Ϫ/Ϫ mice. Overexpression of apoM increased and deficiency of apoM decreased the plasma VLDL/ LDL-cholesterol concentration in Ldlr Ϫ/Ϫ mice. ApoM overexpression did not significantly affect VLDL/LDLcholesterol in ApoE Ϫ/Ϫ mice even though their plasma VLDL/LDL-cholesterol concentrations were increased to the same extent as in Ldlr Ϫ/Ϫ mice. As such, the results could be interpreted as if the effect of apoM on plasma VLDL/LDL levels is dependent on apoE. However, there was no effect of apoM overexpression on plasma VLDL/LDL cholesterol in cholate/cholesterol-fed or chow-fed Wt mice with intact apoE implying that the effect of apoM on plasma VLDL/LDL only is significant in the absence of intact LDL receptors. If these data can be extrapolated to humans, they imply that the association between plasma apoM and LDL cholesterol levels in normal humans with intact LDL receptors for the largest part reflects an effect of plasma LDL clearance on apoM (as discussed above) rather than effects of apoM on plasma LDL metabolism.
Because apoM did not affect plasma VLDL/LDL in ApoE Ϫ/Ϫ or Wt mice, we suspect that apoM does not affect hepatic lipoprotein secretion. We therefore performed turnover studies with radio-iodinated VLDL/LDL to examine whether apoM might affect VLDL/LDL catabolism. The removal from plasma was slower for labeled apoM-enriched VLDL/LDL (isolated from ApoM-Tg H Ldlr Ϫ/Ϫ mice) than for labeled VLDL/LDL from Ldlr Ϫ/Ϫ mice both in Ldlr Ϫ/Ϫ and Lrp1 n2/n2 Ldlr Ϫ/Ϫ mice. Even though the results thus offer support to the idea that apoM impairs the clearance of VLDL/LDL via non-LDL receptor and LRP1 mediated pathways, the data should be interpreted with caution. Hence, in agreement with the observation that apoM rapidly exchanges between lipoprotein fractions, a significant portion of the radioactivity from labeled apoM-enriched VLDL/LDL appeared in the HDL fraction. Nevertheless, the VLDL/LDL associated radioactivity was more slowly removed from plasma when comparing labeled apoM-enriched VLDL/LDL with labeled apoM-poor VLDL/LDL. The LDL receptor and LRP1-independent pathway(s) for VLDL/LDL clearance that may be hindered by apoM is unknown. It could involve scavenger receptors 31 event though we have not seen any effects of murine SRBI deficiency on plasma apoM levels (C Christoffersen, LB Nielsen, unpublished data, 2010).
What might be the physiological meaning of apoM decreasing VLDL/LDL (and possibly apoE-containing HDL) clearance via non-LDL receptor-mediated pathways? ApoM is a lipocalin with ability to bind a small lipophilic ligand(s). 11 Recombinant apoM binds retinol and retinoic acid, but the physiological ligand of apoM is unknown. 39 Normally, the plasma half-life of VLDL/IDL is very rapid compared with LDL and HDL. 33 Thus, we speculate that the inhibitory effect of apoM on lipoprotein clearance may have evolved to delay removal of the lipoproteins that carry apoM, thus serving to maintain apoM (and its ligand) in the circulation.
In contrast to the situation in normal humans with intact LDL receptors and irrespective of the physiological function, the present findings imply that apoM may be a determinant of plasma VLDL and LDL levels in patients with FH. Thus, based on the findings in mice it is conceivable that FH patients have increased plasma apoM concentrations that in turn increases plasma VLDL/LDL. Further elucidation of this hypothetical scenario obviously requires studies that link apoM and VLDL/LDL cholesterol levels in FH individuals. At this stage, there are no known means to manipulate plasma apoM in humans. Recent studies have, however, identified common polymorphisms in the apoM promoter region that may affect apoM plasma levels. 40 It would be interesting to determine whether genetically induced changes in apoM expression might modulate the hypercholesterolemic response to LDL receptor or apoB3500 mutations in humans.
The present studies of hypercholesterolemic mice with altered apoM expression further establish that apoM is capable of retarding the development of atherosclerosis, at least in mice. 14 -16 Remarkably, however, in the setting of LDL receptor deficiency the antiatherogenic effect of apoM was blunted by the proatherogenic effect of raising VLDL/ LDL, especially in female mice. This may reflect that the antiatherogenic effect of apoM is more pronounced in male than in females. Notably, however, apoM overexpression did reduce atherosclerosis in female ApoE Ϫ/Ϫ and cholate/cholesterol-fed female mice. Thus, further studies are needed to resolve the putative gender specific effects of apoM in atherogenesis. The antiatherogenic effect of raising apoM in ApoE Ϫ/Ϫ and cholate/cholesterol-fed mice agrees with previous in vitro findings showing that apoM increases the antiatherogenic properties of HDL by promoting pre␤-HDL formation, increasing the ability of HDL to mobilize cholesterol from foam cells and inhibit oxidation of LDL. 10 It is unknown which of these mechanisms are most important in vivo.
A recent study showed that apoM plasma levels indeed are positively related to pre␤-HDL formation in humans. 16 Nevertheless, the mean plasma apoM concentration was almost identical in patients with cardiovascular disease and controls. 18 It is possible that this lack of association between plasma apoM and cardiovascular risk in humans reflects that a high plasma apoM concentration is linked with high plasma LDL residence times and concentrations. As such, the lack of predictive power of plasma apoM in relationship to human cardiovascular disease does not rule out that increasing plasma apoM might have beneficial effects in human atherogenesis, at least in non-FH patients.
